Changing public opinion about pot isn't easy. Changing America's anti-pot laws is even harder -- here's a blueprint to get it done.
This month marks my 13th year working for marijuana law reform. During this time I've witnessed many successes and many more signs of progress. Nevertheless, it remains frustratingly clear that despite sincere efforts and millions poured into campaigns, very little headway has been made toward attaining the larger, essential goals of the movement -- specifically, abolishing the criminal laws that result in the arrest and prosecution of more than half a million Americans every year for possessing even small amounts of herb and establishing a framework for regulating legal access to marijuana to adults.
Is either one of these goals achievable? Certainly. Is either goal realistic? Not until we as a movement instigate significant shifts in both public attitude and political opinion.
Identifying the problems
For several decades, various organizations have pushed for the establishment of a legal and regulated market for adult cannabis use in the United States. Yet, despite extensive educational efforts and millions poured into various legislative campaigns, it's consistently been shown in opinion polls and at the voting booth that only between a third to 46 percent of Americans endorse legalizing the personal use of cannabis for adults.
As a result, the marijuana law reforms that have been enacted over the past several decades have been limited in scope. Specifically, these legal reforms fall into two distinct categories: "decriminalization" (exempting adult cannabis users from incarceration, but not necessarily arrest, under specified circumstances) and "medicalization" (exempting certain state-authorized medical marijuana patients from state-specific criminal sanctions). To date, 12 states -- almost one-third of the U.S. population -- have enacted limited versions of "decriminalization." Twelve states have also adopted various versions of "medicalization." ...
... follow link for continuation of article:
Alternet DrugReporter